Výsledky vyhledávání

Akademický článek

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial

Autor: Benjamin J. Solomon, M.B.B.S., PhD, Ibiayi Dagogo-Jack, MD, Se-Hoon Lee, MD, Michael J. Boyer, M.B.B.S., PhD, Suresh S. Ramalingam, MD, Enric Carcereny, MD, Enriqueta Felip, MD, PhD, Ji-Youn Han, MD, PhD, Toyoaki Hida, PhD, Brett G.M. Hughes, M.B.B.S., Sang-We Kim, MD, PhD, Makoto Nishio, MD, PhD, Takashi Seto, MD, Tatsuro Okamoto, MD, PhD, Xiaoxi Zhang, PhD, Jean-Francois Martini, PhD, Erjian Wang, MD, PhD, Steven De Beukelaer, MD, Todd M. Bauer, MD

Publikováno v: JTO Clinical and Research Reports, Vol 5, Iss 7, Pp 100685- (2024)

Introduction: The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in ALK-positive or ALK-negative advanced NSCLC, respectively. Methods: Starting d

Externí odkaz: https://doaj.org/article/50d39c846b474baea88547c6b345e6aa

Zobrazit plný text záznamu

Data from Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non–Small Cell Lung Cancer

Autor: Weiwei Tan, Kourosh Parivar, Keith D. Wilner, Michael Amantea, Reza Khosravan, Akintunde Bello, Dana J. Nickens, Erjian Wang

Purpose: We assessed the effect of baseline patient demographic and disease characteristics on the crizotinib pharmacokinetic parameters oral clearance (CL/F), volume of distribution (V2/F), and area under the curve at steady state (AUCss) following

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a06274236be1b2a0878cdd6cd60f0f8
https://doi.org/10.1158/1078-0432.c.6526605.v1

Zobrazit plný text záznamu

Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors

Autor: Erjian Wang, Reza Khosravan, Steven G. DuBois, Katherine A. Janeway

Publikováno v: Cancer Chemotherapy and Pharmacology

Purpose The starting dose of sunitinib in children with gastrointestinal stromal tumors (GIST) was extrapolated based on data in adults with GIST or solid tumors and children with solid tumors. Methods Integrated population pharmacokinetics (PK), PK/

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d84ccddc24d7b1275c01e6d2c97b85ab
http://europepmc.org/articles/PMC8026416

Zobrazit plný text záznamu

Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors

Autor: Cynthia Wetmore, Reza Khosravan, Erjian Wang, Steven G. DuBois

Publikováno v: Cancer Chemotherapy and Pharmacology

Purpose The safety profile of sunitinib in children, including the impact of sunitinib exposure on safety endpoints, was assessed using population pharmacokinetic (PK) and pharmacokinetic–pharmacodynamic (PK–PD) models. Methods Data were from two

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6530387d856e0a9f1fb9d6cb8cc7e68
https://doi.org/10.1007/s00280-020-04106-z

Zobrazit plný text záznamu

Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID‐19

Autor: Manoli Vourvahis, Joanne L. Leaney, Brian Corrigan, Erjian Wang, Bharat Damle

Publikováno v: Clinical Pharmacology and Therapeutics
Clinical Pharmacology & Therapeutics

Azithromycin (AZ) is a broad‐spectrum macrolide antibiotic with a long half‐life and a large volume of distribution. It is primarily used for the treatment of respiratory, enteric, and genitourinary bacterial infections. AZ is not approved for th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ffac0dd7afd98163b0c07397f16fe2d
https://doi.org/10.1002/cpt.1857

Zobrazit plný text záznamu

Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors

Autor: Reza Khosravan, Steven G. DuBois, Cynthia Wetmore, Erjian Wang, Arnauld Verschuur

Publikováno v: European Journal of Drug Metabolism and Pharmacokinetics

Background and Objective Population pharmacokinetic analysis explored the pharmacokinetics of sunitinib and its primary active metabolite, SU012662, in children and evaluated the sunitinib dose(s) that produce comparable plasma exposures to adults re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c7cb69fc41e7401dc9eb5d7a8300673
https://pubmed.ncbi.nlm.nih.gov/33852135

Zobrazit plný text záznamu

Differences between Mice and Humans in Regulation and the Molecular Network of Collagen, Type III, Alpha-1 at the Gene Expression Level: Obstacles that Translational Research Must Overcome

Autor: Stephen H. Clark, Weikuan Gu, Lishi Wang, Hongchao Liu, Hong Chen, Arnold E. Postlethwaite, Yan Jiao, Erjian Wang

Publikováno v: International Journal of Molecular Sciences, Vol 16, Iss 7, Pp 15031-15056 (2015)
International Journal of Molecular Sciences
Volume 16
Issue 7
Pages 15031-15056

Collagen, type III, alpha-1 (COL3A1) is essential for normal collagen I fibrillogenesis in many organs. There are differences in phenotypes of mutations in the COL3A1 gene in humans and mutations in mice. In order to investigate whether the regulatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4afcf834e7aba455922c2e3985b6fc0
http://www.mdpi.com/1422-0067/16/7/15031

Zobrazit plný text záznamu

Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma

Autor: Margaret A. Marshall, Dmitri Pavlov, Dongwoo Kang, Kyun-Seop Bae, Erjian Wang, Kourosh Parivar

Publikováno v: The Journal of Clinical Pharmacology. 54:1108-1116

Tremelimumab, a fully human monoclonal antibody specific for human cytotoxic T-lymphocyte-associated antigen 4, has been studied in clinical trials. We have reported the results of population pharmacokinetics for tremelimumab in 654 metastatic melano

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aa1e3abc26e24a4a6a9e2548f0d145d1
https://doi.org/10.1002/jcph.309

Zobrazit plný text záznamu

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors

Autor: Olga Valota, Justine Yang Bruce, Erjian Wang, Shilpa Gupta, Neeraj Agarwal, Brad Rosbrook, James Larkin, Thomas Powles, M. Dror Michaelson, Roberto Pili, Danielle Murphy, Panpan Wang, Maria Jose Lechuga, Ulka N. Vaishampayan, Russell Z. Szmulewitz, Dale R. Shepard

Publikováno v: The Oncologist

Lessons Learned The combination of axitinib and crizotinib has a manageable safety and tolerability profile, consistent with the profiles of the individual agents when administered as monotherapy. The antitumor activity reported here for the combinat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbe4f89f3491209dd61a0f697230c610
https://doi.org/10.1634/theoncologist.2018-0749

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání